Background {#S1}
==========

Secondary hyperparathyroidism is a common complication of end-stage renal disease (ESRD), which occurs as a result of hyperphosphataemia, hypovitaminosis D and hypocalcaemia. Chronic hyperparathyroidism can result in osteitis fibrosis cystica, also known as brown tumours. Spinal cord compression from a brown tumour is a rare emergency and of the eight reported cases in the literature, this represents the first case while undergoing treatment with sevelamer and cinacalcet. Although cinacalcet may have a role in the metabolic control of hyperparathyroidism, caution needs to be taken in delay or avoidance of parathyroidectomy in severe cases, as it may cause delays in necessary therapy.

Case report {#S2}
===========

A 33-year-old obese aboriginal woman with ESRD secondary to type II diabetes who had been on haemodialysis for 7 years presented on 9 February 2006 with a 3-day history of back pain and progressive leg weakness after a minor fall. She had a known history of severe hyperparathyroidism despite treatment with calcium carbonate 500 mg four times daily, calcitriol 1 mcg three times weekly and sevelamer up to 8 g per day. She had been scheduled for a parathyroidectomy 10 months previously. Her parathyroidectomy was subsequently cancelled after her parathyroid hormone level (PTH) had decreased from 1616 pg/mL (normal 7--50 pg/mL) to 629 pg/mL with the addition of cinacalcet (90 mg orally once a day) over a 3-month period. However, despite maximal doses of sevelamer, calcium carbonate, calcitriol and cinacalcet, her PTH was 615 pg/mL when she presented with spinal cord compression. Physical examination demonstrated normal vitals and cardiac, respiratory and abdominal examinations were also non-contributory. Neurologic examination revealed bilateral hip flexor weakness (left 2/5, right 3/5), patchy saddle anaesthesia and minimal rectal tone. Sensation and proprioception were intact distally. Plantar reflex was flexor on the left, and the right side was not tested due to the presence of a cast for a non-pathological ankle fracture. Laboratory results included calcium 1.83 mmol/L (7.32 mg/dL), phosphate 1.29 mmol/L (3.99 mg/dL), albumin 37 g/L (3.7 g/dL) and alkaline phosphatase of 970 u/L. MRI revealed multiple lesions involving T1 (first thoracic), T7--T11, and L1--S1 (first lumbar to first sacral) vertebrae (Figure [1](#F1){ref-type="fig"}a). Significant spinal cord compression was identified at the T7 and T11 levels (Figure [1](#F1){ref-type="fig"}b). Open surgical biopsy revealed haemosiderin-containing macrophages, collagenous tissue and abundant isomorphic giant cells consistent with a brown tumour (Figure [1](#F1){ref-type="fig"}c). The patient underwent urgent surgical spinal cord decompression and parathyroidectomy. As the lesion was highly vascular, only a partial laminectomy was performed and the T7 level and the remainder of the lesions were treated conservatively. Post-parathyroidectomy her PTH rapidly decreased to 26 pg/mL by 21 March. Her hospital course was complicated by an intensive care unit admission for non-malignant, hemorrhagic pericardial tamponade. Follow-up MRI 80 days later showed significant improvement at all spinal cord levels with some mild residual cord compression at T9--T11. The patient\'s symptoms have improved but she remains wheelchair bound.

![(**a**) Saggital MRI findings at presentation T1 weighted (left), and T2 weighted (right). (**b**) Axial CT findings at presentation of the 11th thoracic vertebral level (left), and 7th thoracic vertebral level (right). (**c**) Pathologic specimen obtained by surgical biopsy showing haemosiderin-stained macrophage (left), and Giant cells (right).](sfn016fig1){#F1}

Discussion {#S3}
==========

Osteitis fibrosis cystica is a pathological state of increased osteoclastic resorption of calcified bone with replacement by fibrous tissue. This is accompanied by foci of haemorrhage and cyst formation \[[@R1]\]. Aggregates of osteoclasts, reactive giant cells and hemorrhagic debris occasionally form masses that may be mistaken for neoplasms and have been called brown tumours. Although cinacalcet has been shown to partially or completely correct calcium, phosphate and PTH levels associated with hyperparathyroidism, these are only surrogate outcomes and there is no direct evidence to support a decrease in hyperparathyroid-related bone disease \[[@R2]\]. In our case the addition of cinacalcet did not prevent the development of brown tumour complications despite the fall in the calcium, phosphate and PTH. Conversely, the decrease in these surrogate markers led to a delay in definitive management with parathyroidectomy, subsequently resulting in spinal cord compression.

There have been five reported cases of brown tumours from secondary hyperparathyroidism \[[@R3]\] resulting in spinal cord compression and an additional three cases due to primary hyperparathyroidism \[[@R8]\] (Table [1](#T1){ref-type="table"}). Cinacalcet use has not been documented in any of these previously reported cases. All eight cases were female with a median age of 45 years (range 24--69 years) and all involved the thoracic spine. Six cases experienced paraparesis and two had paraplegia. Neck or back pain was common to all patients. Calcium levels were reported in six of the eight cases with a median level of 3.4 mmol/L (13.6 mg/dL; range 2.6--4.5 mmol/L, 10.4--18.0 mg/dL). PTH and phosphate levels were not consistently reported. Only three of the eight patients were able to walk unaided post-operatively; two patients required an assist device to walk; one patient remained paraplegic; one patient died from other medical complications; and there is incomplete information regarding the recovery of one patient. Given the small number of cases available, it is not possible to comment on the overall prognosis associated with spinal cord compression related to brown tumours, but this case contributes additional dimension to clinical outcome information on a rare condition.

  Case                Date   Age   Gender   Type of     Renal       Neurologic     Spine level   Calcium level   Outcome
  ------------------- ------ ----- -------- ----------- ----------- -------------- ------------- --------------- ---------------------
  Bohlam *et al*.     1986   69    F        Secondary   ESRD        Paraparesis    T8            4.5             Died
  Masutani *et al*.   2001   39    F        Secondary   ESRD        Paraplegia     T4            3               Walking unaided
  Pumar *et al*.      1990   24    F        Secondary   ESRD        Paraparesis    T8            N/A             N/A
  Fineman *et al.*    1999   37    F        Secondary   ESRD        Paraparesis    T9            2.6             Walking with cane
                                                                    and numbness                                 
  Vandenbussche       2004   37    F        Secondary   ESRD        Paraparesis    T8            N/A             Walking unaided
  *et al*.                                                                                                       
  Shaw *et al*.       1968   58    F        Primary     23 mL/min   Paraparesis    T10           3.7             Walking with walker
  Siu *et al*.        1977   64    F        Primary     16 mL/min   Paraplegia     T10           3.4             Remained paraplegic
  Kashkari *et al*.   1990   51    F        Primary     N/A         Paraparesis    T6--7         3.4             Complete recovery
  Current case        2006   33    F        Secondary   ESRD        Paraparesis    T7, T11       1.83            Wheelchair

This patient was only 12 years old when she was diagnosed with type II diabetes, which, although rare, occurs more commonly in the obese aboriginal patient population. At the time of writing, her diabetes was controlled with glyburide.

To our knowledge this represents the first case of spinal cord compression secondary to a brown tumour in the setting of sevelamer and cinacalcet use. This suggests that even with maximal medical therapy patients may develop serious complications from secondary hyperparathyroidism. Presumably, had the patient had earlier parathyroidectomy, spinal cord compression may have been avoided. Although cinacalcet may have a role in reducing the number of parathyroidectomies performed in the ESRD population, there remains little evidence that it reduces hard clinical outcomes related to secondary hyperparathyroidism. Clearly more needs to be learned about the natural history of hyperparathyroid-associated bone disease in the cinacalcet, sevelamer era. Nephrologists must weigh the risk and benefits of parathyroid surgery against the efficacy of cinacalcet in reducing surrogate markers of metabolic bone disease when deciding how to treat dialysis patients with severe hyperparathyroidism.
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